Bain Capital Invests up to $300M in Cardurion Pharmaceuticals

Bain Capital Life Sciences Leads $200M Growth Investment in Serán Bioscience

September 17, 2024

Pharmaceuticals

Bain Capital Life Sciences led a strategic growth investment of more than $200 million in Serán Bioscience, with existing investor Vivo Capital remaining a key shareholder. The capital will fund a new commercial-scale manufacturing campus in Bend, Oregon, expanding Serán's development, analytical and commercial manufacturing capabilities across multiple drug delivery modalities.

Novo Nordisk Acquires Cardior Pharmaceuticals from EQT Life Sciences

March 25, 2024

Biotechnology

Novo Nordisk has agreed to acquire Cardior Pharmaceuticals for up to EUR 1.025 billion, including an upfront payment and contingent development and commercial milestone payments. Cardior, a Hannover-based clinical-stage biotech focused on RNA-targeted therapies for cardiovascular disease, is currently majority-backed by EQT Life Sciences; the deal is expected to close in Q2 2024 subject to regulatory approvals.

Bain Capital and Kohlberg Lead Strategic Investment in PCI Pharma Services

July 14, 2025

Healthcare Services

PCI Pharma Services, a Philadelphia-based contract development and manufacturing organization (CDMO), received a strategic growth investment co-led by Bain Capital and existing lead investor Kohlberg, with significant reinvestment from Mubadala and a continuing minority stake from Partners Group. The capital will be used to accelerate PCI's organic and inorganic growth, expand sterile fill-finish and specialized manufacturing capacity, and broaden its geographic footprint to support biopharma customers and U.S. pharmaceutical supply-chain resilience.

Bain Capital Private Equity Takes Majority Stake in InnovaCare Health

November 19, 2021

Healthcare Services

Bain Capital Private Equity has signed a definitive agreement to acquire a majority stake in InnovaCare Health, a regional leader in integrated and value-based healthcare services. The investment will support InnovaCare's national expansion and accelerate growth of its physician-led, value-based care model; Summit Partners will remain an equity holder and management will retain significant ownership.

Bain Capital and Bristol Myers Squibb Launch NewCo with $300M to Develop Immunology Therapies

July 31, 2025

Biotechnology

Bristol Myers Squibb (BMS) and Bain Capital have created a new independent biopharmaceutical company (NewCo) to advance five licensed immunology assets, with Bain Capital committing $300 million and support from the Canada Pension Plan Investment Board. BMS licensed three clinical-stage and two Phase 1-ready programs to NewCo and will retain nearly a 20% equity stake while joining the new company's board.

Bain Capital Credit Announces $2.7 Billion of Financing Investments in 2021

February 22, 2022

Financial Services

Bain Capital Credit's Private Credit Group invested $2.7 billion across more than 100 businesses in 2021, supporting refinancing, leveraged buyouts and add-on acquisition activity for middle-market and private equity-backed companies. The announcement highlights the group's role as a lead lender on many commitments and its focus on providing flexible private capital solutions to businesses with EBITDA between $10 million and $150 million.